Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 47 citing articles:

Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Yau-Tuen Chan, Cheng Zhang, Junyu Wu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 38
Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies
D.Y. Luo, Jing Zhou, Shuiliang Ruan, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Manganese Galvanic Cells Intervene in Tumor Metabolism to Reinforce cGAS‐STING Activation for Bidirectional Synergistic Hydrogen‐Immunotherapy
Nailin Yang, Shumin Sun, Jiachen Xu, et al.
Advanced Materials (2025)
Closed Access | Times Cited: 1
Combination locoregional and systemic therapies in hepatocellular carcinoma
Bin‐Yan Zhong, Wenzhe Fan, Justin J. Guan, et al.
˜The œLancet. Gastroenterology & hepatology (2025)
Closed Access | Times Cited: 1
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Soo Young Hwang, Pojsakorn Danpanichkul, Vatche G. Agopian, et al.
Clinical and Molecular Hepatology (2024)
Open Access | Times Cited: 7
Immunotherapy improved the efficacy of TACE or TACE plus MTTs in HCC patients: A meta-analysis
Yusheng Guo, Zhenliang Pan, Xuefeng Kan, et al.
International Immunopharmacology (2025) Vol. 147, pp. 114006-114006
Closed Access
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
Da-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Hepatology (2025)
Closed Access
Combining immune checkpoint inhibitors and molecular-targeted agents with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium tumor thrombus
Suixing Zhong, Jun‐Zhe Yi, Song Chen, et al.
Hepatology International (2025)
Closed Access
Neoadjuvant therapy: Dawn of reducing the high post-surgery recurrence rate of hepatocellular carcinoma
Xiaodong Zhang, Luyi Zhang, Jialiang Luo, et al.
World Journal of Gastrointestinal Surgery (2025) Vol. 17, Iss. 3
Closed Access
Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study
Junfeng Bu, Zihan Li, Die Hu, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Long-Term Outcomes of Transarterial Chemoembolization plus Ablation versus Surgical Resection in Patients with Large BCLC Stage A/B HCC
Yingwen Hou, Tian-Qi Zhang, Li Ma, et al.
Academic Radiology (2025)
Open Access
Protein profiling uncovers IGF-1R inhibition potential of 3-(2-furoyl)-indole scaffolds in hepatocellular carcinoma
Efficiency Myrsing, H. M. Chandra Mouli, Pallaprolu Nikhil, et al.
Future Medicinal Chemistry (2025), pp. 1-16
Closed Access
Prognostic Value of Changes in Combined Child–Pugh Class and ALBI Grade in Hepatocellular Carcinoma Treated with Transcatheter Intra-Arterial Therapy Plus Targeted Therapy and PD-(L)1 Inhibitors
Xiaoyu Huang, Xiaojing Cao, Yaqing Kong, et al.
Journal of Hepatocellular Carcinoma (2025) Vol. Volume 12, pp. 481-496
Open Access
Hepatic arterial infusion chemotherapy combined with lenvatinib and immune checkpoint inhibitor versus lenvatinib for advanced hepatocellular carcinoma: a multicenter study with propensity score and coarsened exact matching
Qunfang Zhou, Huijun Li, Liang Ye, et al.
La radiologia medica (2025)
Open Access
Combined TACE with Targeted and Immunotherapy versus TACE Alone Improves DFS in HCC with MVI: A Multicenter Propensity Score Matching Study
Xiaokun Chen, Xiangan Wu, Peng Wei, et al.
Journal of Hepatocellular Carcinoma (2025) Vol. Volume 12, pp. 561-577
Open Access
Hepatocellular carcinoma resistance to tyrosine kinase inhibitors: Current status and perspectives
Yurun Miao, Xiaojun Yang
World Journal of Gastrointestinal Oncology (2025) Vol. 17, Iss. 4
Closed Access
The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment
Jiayun Jiang, Hui Zhang, Yanjiao Ou, et al.
Immunology Letters (2025), pp. 107003-107003
Closed Access
Strengthening health technology assessment for cancer treatments in Europe by integrating causal inference and target trial emulation
Heiner C. Bucher, Frédérique Chammartin
The Lancet Regional Health - Europe (2025) Vol. 52, pp. 101294-101294
Closed Access
Comparative efficacy of interventional therapy with or without targeted immunotherapy in Child-Pugh B hepatocellular carcinoma patients: a single-center, retrospective study
Xufeng Guo, Man Zhao, Xiaoling Duan, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Fully Covered Stent-TIPS for Advanced HCC Patients with Portal Vein Tumor Thrombus-Related Severe Symptomatic Portal Hypertension
Zechuan Liu, Tianshi Lyu, Jinming Yang, et al.
Journal of Hepatocellular Carcinoma (2025) Vol. Volume 12, pp. 29-41
Open Access
Ultrasound and CT-guided implantation of iodine-125 seeds combined with transarterial chemoembolization for recurrent hepatocellular carcinoma at complex sites after hepatectomy
Y WANG, Jie Feng
Brachytherapy (2025)
Closed Access
A nationwide investigation on imaging follow-up after Locoregional therapy for hepatocellular carcinoma in China: Current practices and challenges
Shuwei Zhou, Chenxin Song, Pei Liu, et al.
European Journal of Radiology (2025), pp. 112057-112057
Closed Access
Long-term survival in a patient with ruptured advanced hepatocellular carcinoma treated with nutritional therapy combined with apatinib and camrelizumab: a case report
Yaohao Liang, Tianyu Ruan, Jiaqian He, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
The role of TACE in the era of immune-targeted therapy for hepatocellular carcinoma: a meta-analysis based on PSM
Jiahao Li, Lei Xian, Xinsen Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular carcinoma: a systematic review and meta-analysis
Hengyu Tian, Chidan Wan
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top